

irradiation in animal models. For fractionated radiotherapy of lung parts correlation between irradiated lung volume and incidence of RIP is presumed but clear data are missing.

Material and methods: 296 consecutively irradiated breast cancer patients (1989–1993) with 302 treated chest wall sites were evaluated. Computer-assisted calculation of dose distribution was performed in all cases. Six weeks after completion of therapy all patients were examined and received chest x-ray (CXR). CXRs were independently evaluated by two radiologists for radiation-induced lung abnormalities confined to the treated lung portion. The irradiated lung volume was calculated according to dose distribution. Patients with radiographically confirmed pneumonitis were compared to a population matched with regard to the lung volume.

Results: Pneumonitis was diagnosed radiologically in 45/302 (14.9%) cases. Lung volume irradiated with a dose of 25 Gy and more in those patients was 79.6–534.8 cc. No difference was seen in the treated lung volume compared to the control group matched for tumor site, operation treatment volume, fractionation, systemic treatment and age. Only the extent of operation had a significant impact on the incidence of pneumonitis and irradiated lung volume.

Conclusion: Our data suggest that the significance of radiation-induced pneumonitis in the irradiated lung volume is minor as expected on the ground of experimental results. The size of irradiated lung volume is the most important factor for the incidence of pneumonitis. In daily routine, the latter correlates with the extent of breast resection.

182 **POSTER**
AN ALTERNATIVE DEVICE FOR PROTON THERAPY: ECRIPAC
L.H. Schwartz¹, K.S. Golovanivsky², M. Bacal², J.M. Buzzi², A. Laugier¹

¹Département de Radiothérapie, Hôpital Tenon, France

²Laboratoire de Physique des Milieux Ionisés, Ecole Polytechnique, Palaiseau, France

Proton beam therapy is a technologically advanced means of achieving extremely precise radiation dose distribution. But development of proton therapy has been impaired by its high cost (20 to 70 millions dollars). We propose a rather radical change for proton therapy since the new device is expected to be not only very compact but also remarkably economic. The device is a plasma accelerator, called ECRIPAC (Electron Cyclotron Resonance Ion Accelerator).

In short, in the new project we want to replace the heavy, large and expensive cyclotrons and synchrotrons by a new type of accelerator yielding similar proton fluxes and energy but exhibiting a much smaller size and weight. The cost of this accelerator should be orders of magnitude smaller. For instance, a length of the order of one meter and weight of less than 300 kg. To produce around 10^{10} protons/s at an energy as high as 200 MeV, it needs only a few kilowatts of average electrical power and a minimum of manpower for its maintenance. Under these conditions, the entire accelerator could be mounted on a revolving chassis, pivoting around the patient, which would facilitate the beam deflection system and change the gantry principle.

The project ECRIPAC of a plasma accelerator is developed by a group of international specialists in France. Its theoretical performance in particle energy and beam current is deduced from analytical and numerical studies undertaken between 1990 and 1993. The results yield beam characteristics very similar to those obtained by the classical accelerators. Thus an experimental development of ECRIPAC has been recently decided. The prototype will be built at Palaiseau.

183 **POSTER**
CT PLANNING OF HDR BREAST IMPLANTS: A CONTRIBUTION TO QUALITY ASSURANCE
D. Seewald, J. Hammer, J. Zoidl, C. Track
Department of Radiation Oncology, Sisters of Mercy Hospital, A-4010 Linz, Austria

The purpose of this presentation is to describe the procedure of the interstitial boost therapy planning in breast cancer irradiation in the Hospital of Sisters of Mercy in Linz, Austria. The use of a boost irradiation at the primary tumour site is associated with an increased local control. Maximum effectiveness of the boost irradiation depends on accurate location of the target volume which is the surgical tumour bed. There are some reports about localization techniques of the boost volume for external irradiation. Less has been reported about the target volume localization of HDR interstitial implants of the breast. We have introduced the development of a treatment planning method to obtain accurately located

interstitial implants and homogenous dose distributions and therefore full coverage of the target volume. At the time of the boost irradiation, treatment planning is started in the simulator room, to define the needle position and therefore the target volume represented by the implanted clips. Then the implantation is done in the afterloading room. A device for patient transportation between Iridium unit, simulator and CT scanner has been constructed. The implanted needles and the clips are visualized by means of the CT-scanner. So the source dwell position and therefore the length to be irradiated can be determined in order to provide adequate coverage of the clipped tumour bed. The isodose distribution and the relationship to the surrounding tissues is obtained by the planning compute of the remote afterloading device. So the source dwell times can be determined if there will be an overdose for the normal tissues. We conclude that this procedure with careful attention to the source position by CT planning results in an accurate treatment of the target volume. The implant and the dose distribution to the surrounding normal tissues are documented by the CT images. The planning procedure is made feasible by the use of the special transportation device and has the advantage of patient immobilization.

184 **POSTER**
RADIOTHERAPY RESULTS IN EARLY STAGE (T1-T2) VOCAL CORD CARCINOMA

M. Şen, R. Çetingöz, İ. Bilkay, S. Sütay, H. Alanyalı, E. Ada, U. Pabuccuoğlu, A. Güneri, S. Sarıoğlu, U. Yılmaz, İ. Kovanlıkaya, K. Ceryan, M. Kınay

Head and Neck Cancer Group of Dokuz Eylül University, Izmir, Turkey

In early stage larynx carcinoma, the function preserving treatment can be performed only if patients are evaluated properly. In this study we present the preliminary results of 44 patients of early stage larynx carcinoma which are treated according to the prospective larynx carcinoma protocol of Dokuz Eylül Head And Neck Cancer Group. Forty-three patients were male and 1 patient was female. The average age is 61 (27–87). Thirty-seven patients were staged as T1N0 and 7 patients as T2N0. In 40 cases, the tumor localization was in the glottic and in 4 cases in the supraglottic area. The tumor histology was squamous cell carcinoma in 36 patients, in-situ carcinoma 7 and small cell carcinoma in 1 patient. Lung cancer was detected as a second primary in 1 patient. Diagnosis was made by biopsy in 28 cases, by stripping in 12 cases, by cordectomy in 1 case, by polypectomy in 1 case, and by mass excision in 2 cases. All cases were treated by radiotherapy alone. Treatments were completed in all cases. The delivered total dose is 66–70 Gy in 33–35 fractions (in 200 cGy fractions). There was total tumor regression in all cases, 2 months after radiotherapy. No serious side effects were observed. The self evaluation of voice quality was revealed as very satisfactory in 43 patients. Only in the cordectomy case the voice quality was unsatisfactory. The case with lung cancer is lost to follow up. Two cases died because of other reasons and the rest are disease free.

185 **POSTER**
OUR TREATMENT PROTOCOL IN NASOPHARYNGEAL CARCINOMA

M. Şen, R. Çetingöz, İ. Bilkay, S. Sütay, H. Alanyalı, U. Yılmaz, E. Ada, U. Pabuccuoğlu, İ. Kovanlıkaya, A. Güneri, M. Alakavuklar, S. Sarıoğlu, K. Ceryan, M. Kınay

Head and Neck Cancer Group of Dokuz Eylül University, Izmir, Turkey

Nasopharynx cancers are classified differently from other types of head and neck cancers by their extensive lymphatic spread and frequent distant metastasis. In most cases RT is the only treatment modality because of the localization. Neoadjuvant chemotherapy studies are held to have better results in the local-regional advanced disease. 39 was treated in our clinic between August 91–June 94. Thirty of the 39 cases were treated according to the NF cancer treatment protocol of Dokuz Eylül University Head and Neck Cancer Group. Our treatment protocol for Stage I–III disease is curative RT and for Stage IV disease both neoadjuvant CT (CDDP + Bleomycin + Methotrexate) and RT. This protocol is activated in October 1992. Twenty-six cases were Stage IV, 3 cases Stage III, 1 case Stage II. Fifteen cases were treated by RT and CT and 15 cases were treated with RT alone. The applied RT technique and total doses are standard in all cases. Each case is irradiated with 50 Gy to the supraclavicular and cervical areas without lymphatic involvement and with 70 Gy irradiation to the primary tumor and to involved cervical lymph node areas. Neoadjuvant CT is applied two courses every 21 days and after subsequent tumor response evaluation, RT was started. Median follow-up period is 22 month (3–40 months). Three cases with